BioVex Press Releases

The press releases in this section of our website are presented for achival purposes only, speak only as of their respective dates and have not been updated.

BIOVEX TO ANNOUNCE UPDATED SURVIVAL DATA FROM A PHASE II CLINICAL STUDY OF ONCOVEXGM-CSF IN METASTATIC MELANOMA AT THE 2009 AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

Woburn, MA -- May 15, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that updated survival data from its Phase II study in metastatic melanoma will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29, 2009 – June 2, 2009 in Orlando, FL.

Senior clinical investigator, Neil N. Senzer, M.D., will present the data in an abstract (number 9035) entitled "Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpes virus in unresectable metastatic melanoma," at ASCO on Monday, June 1, 2009 from 8:00am – 12:00pm EDT during the melanoma poster session located in Level 2, West Hall C.

+ read more

BIOVEX TO REPORT PHASE I/II CLINICAL TRIAL RESULTS FOR THE FRONT LINE TREATMENT OF HEAD AND NECK CANCER WITH ONCOVEXGM-CSF AT THE 2009 AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

Woburn, MA -- May 15, 2009 -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results from a Phase I/II combination study in previously untreated patients with head and neck cancer will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29, 2009 – June 2, 2009 in Orlando, FL.

+ read more

BIOVEX COMMENCES ONCOVEXGM-CSF PHASE 3 TRIAL IN METASTATIC MELANOMA

Woburn, MA. --  April 14, 2009 -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEXGM-CSF in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year.

+ read more

BIOVEX RAISES $40 MILLION IN FIRST CLOSE OF SERIES F FINANCING

Woburn, MA. -- March 30, 2009 --  BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it has raised $40 million in the first close of a series F private financing.

+ read more

BIOVEX ANNOUNCES REGULATORY CLEARANCE TO COMMENCE A CLINICAL STUDY WITH IMMUNOVEXHSV2; A VACCINE CANDIDATE FOR GENITAL HERPES

Woburn, MA – August 20, 2008 – BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted BioVex’s Clinical Trial Application to conduct a Phase I clinical study testing the safety and immunogenicity of its lead infectious disease candidate for genital herpes, ImmunoVEXHSV2.

+ read more

BIOVEX REPORTS POSITIVE PHASE II CLINICAL TRIAL RESULTS OF ONCOVEXGM-CSF IN METASTATIC MELANOMA AT THE 2008 AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

Chicago, IL – June 1, 2008 – BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced positive results from its Phase II clinical trial of OncoVEXGM-CSF, an oncolytic for the treatment of advanced metastatic melanoma, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

+ read more

BIOVEX TO REPORT PHASE II CLINICAL TRIAL RESULTS OF ONCOVEXGM-CSF IN METASTATIC MELANOMA AT THE 2008 AMERICAN SOCIETY OF CLINICAL ONCOLOGY MEETING

Woburn, MA, May 16, 2008 BioVex Inc, a biotechnology company developing clinical stage products in oncology and infectious disease, announced today that the abstract describing the interim results from its Phase II clinical trial of OncoVEXGM-CSF in advanced metastatic melanoma is now available at the American Society of Clinical Oncology (ASCO) website

+ read more

BIOVEX AGREES SPA WITH THE FDA FOR A PIVOTAL STUDY WITH ONCOVEXGM-CSF IN METASTATIC MELANOMA AND ANNOUNCES PRESENTATION OF PHASE II RESULTS AT ASCO

FDA agrees to first SPA for an oncolytic product

Woburn, MA, April 22nd, 2008 – BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEXGM-CSF in previously treated patients with metastatic melanoma. The agreement was made under the special Protocol Assessment (SPA) procedure.

+ read more

BIOVEX TO PRESENT AT THE JPMORGAN 26TH ANNUAL HEALTHCARE CONFERENCE

January 2, 2008 – BioVex Inc today announced that it will present at the JPMorgan 26th Annual Healthcare Conference at 2:30 p.m. PT on Wednesday, January 9, 2008. The conference is being held at Westin St. Francis in San Francisco, California.

+ read more

BIOVEX CLOSES SECOND ROUND OF SERIES E FINANCING
Second and Final Close Completes $35 Million Financing

Woburn, MA, November 15 2007 – BioVex Inc, a clinical stage company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it had completed its Series E financing, concurrent with the completion of a venture debt transaction, raising a total of $35m of funds. 

+ read more

BIOVEX APPOINTS GENZYME EXECUTIVE. JAN VAN HEEK, AS CHAIRMAN OF THE BOARD OF DIRECTORS

Woburn, MA, October 25th, 2007 – BioVex Inc announced today that it has appointed Jan Van Heek, age 58, as Chairman of the Board of Directors.

+ read more

BIOVEX APPOINTS DR LEONARD POST TO THE BOARD OF DIRECTORS

Woburn, MA, September 20th, 2007 – BioVex Inc announced today that it has appointed Dr. Leonard Post, age 55, to its Board of Directors.

Press Release September 20 2007

BIOVEX APPOINTS DR THADDEUS PULLANO AS VP, QUALITY ASSURANCE

Woburn, MA, August 15, 2007

BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Thaddeus Pullano, age 53, as Vice President of Quality Assurance.

Press Release August 15 2007

BIOVEX RAISES $22 MILLION IN FIRST CLOSE OF SERIES E FINANCING

Woburn MA July 9 2007

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it had raised $22m in the first close of a series E private financing.

The placement was led by Triathlon Medical Ventures who were joined by new investor New Science Ventures as well as existing investors including ABN Amro (Forbion), Avalon Ventures, Credit Agricole Private Equity, GeneChem Management of Montreal, Innoven Partners and Scottish Equity Partners.

Press Release July 9 2007

ONCOVEXGM-CSF CLINICAL TRIALS RESULTS PUBLISHED

November 21 2006: The results of BioVex's Phase I clinical trial of OncoVEX GM-CSF in a range of solid tumors have been published in the November 15 issue of Clinical Cancer Research (Hu et al : Clin Cancer Res 2006; 12 (22) 6737-6747). The paper demonstrates that OncoVEX GM-CSF was well tolerated and could be safely administered using a multi-dose protocol. Evidence of an antitumor effect was seen. The paper can be viewed here (by kind permission of the American Association for Cancer Research). OncoVEX GM-CSF is now in a Phase II clinical trial (melanoma) and a Phase I/II clinical trial (head and neck cancer).

top